Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group
Authors:
- Mathew S. MaurerMMMathew S. Maurer
- Preston DunnmonPDPreston Dunnmon
- Mariana FontanaMFMariana Fontana
- Cristina Candida QuartaCQCristina Candida Quarta
- Krishna PrasadKPKrishna Prasad
- Ronald M. WittelesRWRonald M. Witteles
- Claudio RapezziCRClaudio Rapezzi
- James SignorovitchJSJames Signorovitch
- Isabelle LousadaILIsabelle Lousada
- Giampaolo MerliniGMGiampaolo Merlini
Open Access
- 25 March 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 15 (6) , e009038
Abstract
Immunoglobulin light chain amyloidosis is a rare, multisystemic, phenotypically heterogenous disease affecting cardiovascular, renal, neurological, and gastrointestinal systems to varying degrees. Its underlying cause is a plasma cell dyscrasia characterized by misfolding of monoclonal immunoglobulin light chains which leads to aggregation and deposition of insoluble amyloid fibrils in target organs. Prognosis is primarily dependent on extent of cardiac involvement and depth of hematologic response to treatment. To facilitate development of new therapies, a public-private partnership was formed between the nonprofit Amyloidosis Research Consortium and the US Food and Drug Administration Center for Drug Evaluation and Research. In 2020, the Amyloidosis Forum launched an initiative to identify novel/composite end points and analytic strategies to expedite clinical trials for development of new therapies for the primary hematologic disorder and organ system manifestations. Specialized working groups identified organ-specific end points; additional working groups reviewed health-related quality of life measures and statistical approaches to data analysis. Each working group comprised amyloidosis experts, patient representatives, statisticians, and representatives from the Food and Drug Administration, the UK Medicines and Healthcare Products Regulatory Agency, and pharmaceutical companies. This review summarizes the proceedings and recommendations of the Cardiac Working Group. Using a modified Delphi method, the group identified, reviewed, and prioritized cardiac end points relevant to immunoglobulin light chain amyloidosis in the context of an antiplasma cell therapy. Prioritized cardiovascular end points included overall survival, hospitalization, N-terminal pro-B-type natriuretic peptide level, 6-minute walk test, Kansas City Cardiac Questionnaire, and cardiac deterioration progression-free survival. These recommended components will be further explored through evaluation of clinical trial datasets and formal guidance from regulatory authorities.Keywords
This publication has 79 references indexed in Scilit:
- Noncontrast T1 Mapping for the Diagnosis of Cardiac AmyloidosisJACC: Cardiovascular Imaging, 2013
- Quantification of Myocardial Extracellular Volume Fraction in Systemic AL AmyloidosisCirculation: Cardiovascular Imaging, 2013
- New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival OutcomesJournal of Clinical Oncology, 2012
- Health-related quality of life (HRQL) for individuals with self-reported chronic physical and/or mental health conditions: panel survey of an adult sample in the United StatesHealth and Quality of Life Outcomes, 2012
- AL AmyloidosisOrphanet Journal of Rare Diseases, 2012
- The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosisBlood, 2010
- Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) AmyloidosisJournal of Clinical Oncology, 2010
- Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: new evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosisAmyloid, 2009
- Continental Differences in Clinical Characteristics, Management, and Outcomes in Patients Hospitalized With Worsening Heart FailureJACC, 2008
- Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in ALBlood, 2006